Market Place
Sourcing Support
PDS Biotech`s Data VERSATILE-002 Phase 2 Head and Neck Cancer
25 Aug 2025 //
GLOBENEWSWIRE
PDS Biotech Q2 2025 Financial Results and Clinical Updates
13 Aug 2025 //
GLOBENEWSWIRE
PDS Bio Colorectal Trial Advances to Stage 2 After Positive Data
10 Jul 2025 //
GLOBENEWSWIRE
PDS Biotech Hosts Event on Versamune HPV for HPV16+ HNSCC
09 Jun 2025 //
GLOBENEWSWIRE
PDS Biotech Reveals Positive Data on Versamune® HPV at ASCO 2025
02 Jun 2025 //
GLOBENEWSWIRE
PDS Bio to Present Positive Data on Versamune HPV at 2025 ASCO
22 May 2025 //
GLOBENEWSWIRE
PDS Biotech at A.G.P. Virtual Annual Healthcare Company Showcase
20 May 2025 //
GLOBENEWSWIRE
PDS Biotech Reports Q1 2025 Results and Clinical Update
14 May 2025 //
GLOBENEWSWIRE
PDS Biotechnology Reports Inducement Grant Under Nasdaq Rule
09 May 2025 //
GLOBENEWSWIRE
PDS Bio Reveals 2 Preclinical Influenza Data at IMMUNOLOGY2025
08 May 2025 //
GLOBENEWSWIRE
PDS Biotech to Hold Conference Call for Q1 2025 Results
07 May 2025 //
GLOBENEWSWIRE
PDS Biotech to Present Multiple Abstracts at 2025 ASCO Meeting
23 Apr 2025 //
GLOBENEWSWIRE
PDS Biotech to Present Preclinical Influenza Data at IMMUNOLOGY2025
16 Apr 2025 //
GLOBENEWSWIRE
PDS Biotech to Present PDS01ADC Clinical Data at AACR 2025
08 Apr 2025 //
GLOBENEWSWIRE
PDS Biotech Reports 2024 Financial Results and Clinical Update
27 Mar 2025 //
GLOBENEWSWIRE
PDS Biotech to Present at 2025 CAGLA NeauxCancer Conference
25 Mar 2025 //
GLOBENEWSWIRE
PDS Biotech to Hold Conference Call for 2024 Financial Results
18 Mar 2025 //
GLOBENEWSWIRE
PDS Biotech Leadership to Participate in March Conferences
11 Mar 2025 //
GLOBENEWSWIRE
PDS Biotech Starts Ph3 Versatile-003 Trial Of Versamune In HPV16+ HNC
07 Mar 2025 //
GLOBENEWSWIRE
PDS Biotech Announces $22M Direct Offering Under Nasdaq Rules
27 Feb 2025 //
GLOBENEWSWIRE
PDS Biotech Reports Positive Data In Recurrent/Metastatic HPV Cancers
26 Feb 2025 //
GLOBENEWSWIRE
PDS Biotech: Versamune® HPV Results in IMMUNOCERV Trial Published
24 Feb 2025 //
GLOBENEWSWIRE
PDS Biotech To Join B. Riley Precision Oncology Conference
20 Feb 2025 //
GLOBENEWSWIRE
PDS Biotech: Inducement Grant Under Nasdaq LR 5635(c)(4)
06 Dec 2024 //
GLOBENEWSWIRE
PDS Biotech to Host Key Opinion Leader Event on Dec 17
03 Dec 2024 //
GLOBENEWSWIRE
PDS Biotech Provides Clinical Update & Q3 2024 Results
14 Nov 2024 //
GLOBENEWSWIRE
PDS Biotech to Announce Q3 Results on Nov 14 at 8:30 AM ET
06 Nov 2024 //
GLOBENEWSWIRE
PDS Biotech Presents Rationale For Prostate Cancer Trial Design
22 Oct 2024 //
GLOBENEWSWIRE
PDS Biotech Reports 84.4% Survival Rate in Cervical Cancer
02 Oct 2024 //
GLOBENEWSWIRE
PDS Biotech Announces VERSATILE-002 Results At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
PDS Biotech to Present Updated Versatile Data at ESMO Congress
09 Sep 2024 //
GLOBENEWSWIRE
PDS Biotech to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
PDS Biotech Reports Q2 2024 Results And Provides Business Update
13 Aug 2024 //
GLOBENEWSWIRE
PDS Biotech Abstract Accepted For Oral Presentation At ASTRO Meeting
08 Aug 2024 //
GLOBENEWSWIRE
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
07 Aug 2024 //
GLOBENEWSWIRE
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024
05 Aug 2024 //
GLOBENEWSWIRE
PDS Biotech Aligns With FDA On Phase 3 Head And Neck Cancer Trial
01 Aug 2024 //
GLOBENEWSWIRE
PDS Biotech To Host Clinical Program Update Call On August 1
31 Jul 2024 //
GLOBENEWSWIRE
PDS Biotech to Participate at BTIG Virtual Biotechnology Conference
29 Jul 2024 //
GLOBENEWSWIRE
PDS Biotech Provides Business Update, Reports Q1 2024 Financials
15 May 2024 //
GLOBENEWSWIRE
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
09 May 2024 //
GLOBENEWSWIRE
PDS VERSATILE-002 Trial Meets Endpoints In HPV16+ Head/Neck Cancer
09 May 2024 //
GLOBENEWSWIRE
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
07 May 2024 //
GLOBENEWSWIRE
PDS Biotechnology Announces Details of Virtual KOL Event
03 May 2024 //
GLOBENEWSWIRE
PDS Biotech KOL Event On Versamune-Keytruda Head/Neck Cancer Phase 2 Data
23 Apr 2024 //
GLOBENEWSWIRE
PDS Biotech Announces Strategy Update and Reports FY23 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
PDS Biotech Announces Publication of Preclinical Research for Infectimune
13 Mar 2024 //
GLOBENEWSWIRE
PDS Biotech Announces Retirement of Lauren V. Wood, M.D.
22 Jan 2024 //
GLOBENEWSWIRE
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
16 Jan 2024 //
GLOBENEWSWIRE
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
28 Nov 2023 //
GLOBENEWSWIRE
PDS Biotech Announces Data from NCI-Led Phase 2 Clinical Trial of PDS0101
09 Nov 2023 //
GLOBENEWSWIRE
PDS Biotech Announces Conference Call for Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
PDS Bio Announces Study Results in HPV-Positive Head and Neck Cancer Patients
23 Oct 2023 //
GLOBENEWSWIRE
PDS Biotech Announces Immune Response Data from Ph 1/2 Trial Evaluating PDS0301
11 Oct 2023 //
GLOBENEWSWIRE
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint
03 Oct 2023 //
GLOBENEWSWIRE
PDS Biotech Announces PDS0101 Associated with Decline in Circulating Tumor DNA
02 Oct 2023 //
GLOBENEWSWIRE
PDS Biotech to Present at the LD Micro Main Event XVI
26 Sep 2023 //
GLOBENEWSWIRE
PDS Biotech Reschedules Key Opinion Leader Roundtable
25 Sep 2023 //
GLOBENEWSWIRE
PDS Biotech Announces PDS0202 Elicits Active Neutralization of Influenza Strains
20 Sep 2023 //
GLOBENEWSWIRE
PDS Biotech to Participate in the 2023 Cantor Fitzgerald Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
